Cytiva iCELLis™ 500+ Fixed-Bed Bioreactor System

Overview

The Cytiva iCELLis™ 500+ Fixed-Bed Bioreactor System is an engineered, single-use, integrated platform for high-density adherent cell culture in biopharmaceutical manufacturing—specifically optimized for viral vector production, vaccine development, and gene therapy applications. It operates on the principle of fixed-bed perfusion, where cells attach and proliferate on a three-dimensional porous carrier matrix housed within a sealed, pre-sterilized bioreactor chamber. This architecture eliminates mechanical agitation, minimizes hydrodynamic shear stress, and ensures uniform nutrient delivery and waste removal via a patented cascade flow distribution system. Unlike conventional stirred-tank or multi-layer flask systems, the iCELLis™ 500+ delivers up to 500 m² of available surface area within a compact footprint—enabling scalable, reproducible, and process-intensified cultivation of anchorage-dependent mammalian cells such as Vero, MRC-5, HEK293, and CHO-S.

Key Features

• Pre-validated, fully integrated single-use bioreactor with factory-installed, calibrated sensors (temperature, dissolved oxygen, pH, and optional biomass)
• Double-jacketed vessel with external temperature control unit (TCU) enabling precise thermal regulation across 20–40 °C
• Cascade flow recirculation system ensuring homogeneous media distribution, enhanced mass transfer, and efficient CO₂ stripping without foam generation
• Magnetically driven impeller physically isolated from the fixed bed—eliminating direct mechanical contact with cell-laden carriers and preserving viability
• Low-inoculum capability: supports seeding at densities as low as 3,000 cells/cm², reducing upstream cell expansion burden
• Scalable design: identical fluid dynamics and mass transfer characteristics between iCELLis™ Nano (0.53–4 m²) and iCELLis™ 500+ (60–500 m²), enabling linear, predictive scale-up from feasibility studies to commercial manufacturing
• Compact footprint: 500 m² system occupies less than 1.2 m² floor space—equivalent to ~794 ten-layer cell factories or ~5,882 roller bottles (850 cm² each)

Sample Compatibility & Compliance

The iCELLis™ 500+ accommodates a broad range of anchorage-dependent cell lines used in viral propagation and recombinant protein expression—including but not limited to Vero, MRC-5, BHK-21, MDCK, and human embryonic kidney (HEK293) variants. Its closed, single-use construction mitigates cross-contamination risk and aligns with current Good Manufacturing Practice (cGMP) requirements for clinical- and commercial-stage bioproduction. The system supports audit-ready documentation packages, including Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols. Sensor data logging complies with FDA 21 CFR Part 11 requirements when integrated with validated SCADA or MES platforms (e.g., AVEVA System Platform). All wetted components are manufactured from USP Class VI-certified materials and undergo gamma irradiation sterilization.

Software & Data Management

The iCELLis™ 500+ is controlled via Cytiva’s proprietary BioProcess Control Software (BPCS), which provides real-time monitoring, automated parameter adjustment, and secure electronic recordkeeping. The software supports configurable alarm thresholds, trend analysis, and export of time-stamped CSV/Excel reports compliant with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available). Audit trails capture all user actions, setpoint changes, and calibration events. Integration with enterprise systems (LIMS, MES, ERP) is achievable through OPC UA or Modbus TCP interfaces. Optional biomass sensor output enables indirect, non-invasive estimation of viable cell density—supporting feed-forward control strategies during perfusion runs.

Applications

• Viral vector production (AAV, lentivirus, retrovirus) for gene therapy clinical trials and commercial supply
• Live-attenuated and inactivated vaccine manufacturing (e.g., rabies, influenza, RSV)
• Monoclonal antibody and therapeutic protein expression in engineered adherent cell lines
• Process intensification studies comparing fixed-bed vs. microcarrier-based suspension culture
• Regulatory filing support: generation of robust, consistent process data packages meeting ICH Q5A, Q5B, and Q5D expectations
• GMP-compliant tech transfer between R&D, pilot, and commercial facilities

FAQ

What is the maximum surface area supported by the iCELLis™ 500+ system?

The iCELLis™ 500+ offers a scalable fixed-bed surface area ranging from 60 m² to 500 m², configurable in increments to match process-specific productivity targets.
Can the system operate in both batch and perfusion modes?

Yes—the platform supports flexible operation modes, including fed-batch, continuous perfusion, and hybrid strategies, with programmable media exchange rates and harvest scheduling.
Is the iCELLis™ 500+ suitable for regulatory submissions?

Yes—Cytiva provides comprehensive validation support documentation, including sensor traceability, material certifications, and qualification templates aligned with ISO 13485 and Annex 1 (EU GMP) expectations.
How does the cascade flow system improve oxygen transfer efficiency?

The gravity-driven, segmented flow path creates laminar, high-surface-area contact between culture medium and gas-permeable membranes—achieving k_La values comparable to stirred-tank reactors while maintaining shear-sensitive cell integrity.
Are consumables supplied pre-sterilized and ready-to-use?

All single-use bioreactor cassettes, tubing sets, and sensor modules are gamma-irradiated, certified sterile, and delivered in double-bagged, ISO Class 5 cleanroom packaging with full CoA and CoC documentation.